Oral targeted therapy slows pancreatic cancer growth, improves overall survival - ASCO

Cancer research · Pancreatic cancer · KRAS

Daraxonrasib, a RAS(ON) multi-selective inhibitor, nearly doubled overall survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) compared to chemotherapy.

Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Original source

Related signals

• Pancreatic cancer
• Modified FOLFIRINOX improves survival compared to gemcitabine in resected pancreatic cancer
• Recent Advances in the Treatment of Pancreatic Cancer
• Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
• EUROPAC Researching Hereditary Pancreatic Diseases